

Validity of Canadian Discharge Abstract Data for Hypertension and Diabetes from 2002 to 2013

Journal:	<i>CMAJ</i>
Manuscript ID:	CMAJ-15-1030
Manuscript Type:	Research - Descriptive study
Date Submitted by the Author:	01-Sep-2015
Complete List of Authors:	Jiang, Jason; University of Calgary, Community Health Sciences Beck, Cynthia; University of Calgary, Community Health Sciences; University of Calgary, Psychiatry James, Matthew; University of Calgary, Community Health Sciences; University of Calgary, Medicine Lu, Mingshan; University of Calgary, Community Health Sciences; University of Calgary, Economics Quan, Hude; University of Calgary, Community Health Sciences
Keywords:	Statistics and Research Methods, Public Health, Cardiac Disease, Coronary, Diabetes, Hypertension
More Detailed Keywords:	
Abstract:	<p>Background Surveillance using coded administrative health data has shown that the prevalence of hypertension and diabetes in Canada has increased significantly in the last 10 years. These findings requires an assumption that the data validity for hypertension and diabetes coding is stable over time. We tested this assumption by examining the temporal trends of the Canadian hospital discharge abstract data (DAD) in the validity of hypertension and diabetes.</p> <p>Methods Using a clinical registry database of the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) as a reference standard, we evaluated DAD validity in recording hypertension and diabetes in Alberta. APPROACH contains data on all Alberta residents who have received cardiac catheterization, and includes prospective ascertainment of comorbidities prior to each procedure. We linked DAD and APPROACH between 2002 and 2013. Temporal trends in sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated for both hypertension and diabetes in the DAD.</p> <p>Results We matched 63,483 patients between the DAD and APPROACH. The validity of DAD for hypertension and diabetes remained mostly consistent over time. Sensitivity, specificity, PPV and NPV ranged from 61% to 87% for hypertension and 81% to 98% for diabetes, between 2002 and 2013. No significant differences in the validity of codes were found across</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	subgroups by age, sex, or hospital location. Conclusion DAD validity for hypertension and diabetes remained fairly consistent between 2002 and 2013. Our findings support the use of DAD for hypertension and diabetes surveillance in hospital settings.

SCHOLARONE™
Manuscripts

Confidential

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Validity of Canadian Discharge Abstract Data for Hypertension and Diabetes from 2002 to 2013

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

**Authors: Jason Jiang¹ MSc, Cynthia A Beck^{1,2} MD MSc, Matthew James^{1,3} MD PhD,
Mingshan Lu^{1,4} PhD, Hude Quan¹ MD PhD**

1 Department of Community Health Sciences, University of Calgary, Calgary, Canada

2 Department of Psychiatry, University of Calgary, Calgary, Canada

3 Department of Medicine, University of Calgary, Calgary, Canada

4 Department of Economics, University of Calgary, Calgary, Canada

Correspondence:

Dr. Hude Quan

Professor

Department of Community Health Sciences, University of Calgary

3280 Hospital Dr. NW

Calgary, Alberta, Canada, T2N 4Z6

Telephone: (403) 210-8617

E-mail: hquan@ucalgary.ca

Word Count: 2054

Abstract***Background***

Surveillance using coded administrative health data has shown that the prevalence of hypertension and diabetes in Canada has increased significantly in the last 10 years. These findings requires an assumption that the data validity for hypertension and diabetes coding is stable over time. We tested this assumption by examining the temporal trends of the Canadian hospital discharge abstract data (DAD) in the validity of hypertension and diabetes.

Methods

Using a clinical registry database of the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) as a reference standard, we evaluated DAD validity in recording hypertension and diabetes in Alberta. APPROACH contains data on all Alberta residents who have received cardiac catheterization, and includes prospective ascertainment of comorbidities prior to each procedure. We linked DAD and APPROACH between 2002 and 2013. Temporal trends in sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated for both hypertension and diabetes in the DAD.

Results

We matched 63,483 patients between the DAD and APPROACH. The validity of DAD for hypertension and diabetes remained mostly consistent over time. Sensitivity, specificity, PPV and NPV ranged from 61% to 87% for hypertension and 81% to 98% for diabetes, between 2002 and 2013. No significant differences in the validity of codes were found across subgroups by age, sex, or hospital location.

1
2
3 ***Conclusion***
4

5
6 DAD validity for hypertension and diabetes remained fairly consistent between 2002 and 2013.
7

8
9 Our findings support the use of DAD for hypertension and diabetes surveillance in hospital
10
11 settings.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Confidential

Introduction

Surveillance of chronic diseases has been established in many countries for monitoring disease burden and evaluating prevention and therapeutic programs. Temporal trends in disease prevalence are also used to forecast population health status and health resource needs. These trends inform health care policy such as resource allocation. The Public Health Agency of Canada (PHAC) created the Canadian Chronic Disease Surveillance System (CCDSS) to provide governments and the public with new knowledge in order to inform efforts to reduce the risk of developing chronic conditions [1]. Collaborating with provincial and territorial health ministries, the system has successfully tracked hypertension and diabetes using administrative health data. According to CCDSS, from 1998 to 2008, hypertension prevalence in Canada increased from 12.5% to 19.6%; diabetes prevalence from 3.3% to 5.4% [2,3]. The rate of increasing prevalence is alarming and has raised important health policy and chronic disease prevention questions. However, before interpreting these temporal trends in disease prevalence, potential errors from surveillance methods must be excluded or adjusted for.

A major question that remains unexamined is whether data validity has remained consistent over the time period of this surveillance program. While improving data quality over time is generally a good thing, it could be problematic for interpreting temporal trends in disease surveillance. For example, improving sensitivity of disease detection over time will result in increases in prevalence estimates that exceed those in reality. The CCDSS monitors disease burden using diagnostic codes from the hospital discharge abstract database (DAD) and the physician claims database [1]. DAD contains information on all admissions at acute care facilities and physician claims captures billing data from physician visits. DAD and physician

1
2
3 claims are attractive sources for disease surveillance because both readily available, and cover
4 large populations of Canada [4].
5
6
7

8
9 To assess if the above question has been addressed, we reviewed the literature. The
10 published studies assessed a relatively short time period, usually only conducting two or three
11 comparisons over a maximum of five years [5-14]. To fill this gap, we conducted this study to
12 examine the validity of administrative codes from the DAD for hypertension and diabetes from
13 2002 to 2013. A prospective clinical registry, the Alberta Provincial Project for Outcome
14 Assessment in Coronary Heart Disease (APPROACH) database, was used as the reference
15 standard. Our hypothesis is that hypertension and diabetes have been coded with increasing
16 accuracy over time; contributing to their apparent rapid increase of prevalence in CCDSS.
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31 **Methods**

32 *Data Sources: DAD and APPROACH*

33
34
35
36
37 DAD contains information on all inpatient discharges in Alberta. After the patient is
38 discharged, professional coders translate the diagnosis on medical charts into International
39 Classification of Diseases (ICD) codes [15]. These ICD codes are then recorded in DAD, and
40 used (eg. by CCDSS) in the calculation of chronic disease prevalence. Coders are primarily
41 instructed to code conditions contributing to the hospitalization [16]. In Alberta, up to 50
42 conditions can be recorded using ICD-10 for each admission.
43
44
45
46
47
48
49
50
51

52 The APPROACH database is a prospective clinical registry that records detailed clinical
53 information, including comorbidities, on patients undergoing coronary catheterization in Alberta
54 since 1995. Comorbidity data is collected directly by clinicians and catheterization laboratory
55
56
57
58
59
60

1
2
3 staff prior to each procedure [17]. The fact that patient information is collected prospectively in
4
5 the clinical setting provides three major advantages. First, data collection follows a fixed
6
7 structure and format. APPROACH contains a required form asking clinicians to enter
8
9 information for a fixed set of comorbidities, whereas in DAD, coders are free to enter
10
11 information on as many or as few conditions as they see fit. Second, the direct collection of data
12
13 in the clinical setting reduces the chance of error due to data translation in APPROACH, whereas
14
15 the DAD coders must collect and interpret information from medical charts that were written by
16
17 clinicians. Third, APPROACH contains routine processes that check for data quality and
18
19 completeness. Further, procedures are in place to continuously standardize and improve
20
21 measurement and capture of comorbidities. These attributes of APPROACH make it an ideal
22
23 choice for our reference standard.
24
25
26
27
28
29

30 Patient data from APPROACH were linked with DAD from 2002 to 2013 using the
31
32 unique identifier of provincial health number (PHN). The data unit for APPROACH is patients,
33
34 but in DAD it is admissions. Thus one APPROACH patient could be linked with multiple
35
36 admissions. To avoid this, we selected a single index admission from DAD for each linked
37
38 patient. For the index admission, we chose the admission where the catheterization date falls in
39
40 between the admission and discharge date.
41
42
43
44

45 *Study Variables*

46
47 In DAD hypertension was defined using the ICD-10 codes: I10.x, I11.x-I13.x, I15.x.
48
49 Diabetes was defined using the ICD-10 codes: E10.x, E13.10, E13.12, E14.10, E14.12, E11.x,
50
51 E13.0, E14.0. Hyperlipidemia, heart failure, cerebrovascular disease, peripheral vascular disease
52
53 (PVD) and chronic obstructive pulmonary disease (COPD) were assessed as possible
54
55 confounding comorbidities, and were defined using previously validated codes [18].
56
57
58
59
60

1
2
3 In APPROACH, clinicians diagnose presence or absence of these conditions at the time
4 of catheterization following clinical guidelines and practice. Information on age, sex, and
5 hospital location was obtained from APPROACH.
6
7
8
9

10 11 12 13 14 **Data Analysis**

15
16
17 Descriptive statistics were employed to describe study populations. Hypertension and
18 diabetes prevalence differences between 2002 and 2013 for both APPROACH and DAD were
19 calculated, along with a 95% confidence interval. Sensitivity, specificity, positive predictive
20 value (PPV) and negative predictive value (NPV) for DAD recording of hypertension and
21 diabetes were calculated for each year using APPROACH as the reference standard. These
22 estimates were then stratified by age, sex, and hospital location to assess whether these factors
23 significantly affected study outcomes.
24
25
26
27
28
29
30
31
32

33 34 35 36 37 **Results**

38
39 Of 63,483 patients who were linked between DAD and APPROACH, 70.5% were male
40 and the average age was 62.6 years in 2013 (Table 1). The prevalence of hypertension was
41 57.8% in DAD and 57.4% in APPROACH and prevalence of diabetes was 23.6% in DAD and
42 26.0% in APPROACH in 2013 (Table 2). For both hypertension and diabetes, the prevalence
43 was similar for DAD and APPROACH, respectively across age, sex and hospital location over
44 the entire study period (Figure 1; Table 2). There was no statistically significant change or very
45 minor changes in disease prevalence over time in both APPROACH and DAD (Table 2).
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The validity of DAD coding for hypertension and diabetes, using APPROACH as a
4 reference standard, also remained consistent over time (Figure 2). For hypertension, overall
5 sensitivity ranged from 74.6% to 82.5%, specificity ranged from 71.0% to 80.9%, PPV ranged
6 from 79.3% to 87.0% and NPV ranged from 65.5% to 78.0% (Table 3). When looking at the
7 overall trend, the validity of hypertension coding in DAD remained mostly consistent from 2002
8 to 2013.
9
10
11
12
13
14
15
16
17

18 Validity of DAD coding of diabetes was also high (Table 3). Overall sensitivity ranged
19 from 83.8% to 92.1%, specificity ranged from 93.9% to 97.0%, PPV ranged from 81.5% to
20 90.5%, and NPV ranged from 94.5% to 97.6%. Similar to the results for hypertension coding, the
21 overall trend of diabetes coding in DAD was mostly consistent from 2002 to 2013.
22
23
24
25
26
27

28 The validation trends for hypertension and diabetes coding were stratified by age, sex,
29 and hospital location. There were no significant differences in regards to validation trends for
30 either hypertension or diabetes, between those aged 18-64 compared with those aged 65 and up,
31 or between males and females, or between Calgary and Edmonton hospitals (these results were
32 not reported here).
33
34
35
36
37
38
39
40
41
42
43

44 **Interpretation**

45
46 We examined the performance of DAD coding for hypertension and diabetes between
47 2002 and 2013 to determine whether changes have occurred in diagnostic coding validity over
48 time, because such changes could influence the chronic disease surveillance estimates of these
49 two common conditions. Our study leads to three main findings: 1) hypertension and diabetes
50 coding in the DAD provided similar prevalence estimates to those obtained from a prospective
51
52
53
54
55
56
57
58
59
60

1
2
3 clinical registry; 2) current coding algorithms using the DAD had high validity for hypertension
4 and diabetes, reflected in high values of sensitivity, specificity, PPV and NPV; and 3) validity
5 was fairly consistent over 12 years and across age groups, sex and hospital locations. These
6 findings support the use of the DAD for hypertension and diabetes surveillance, and suggest that
7 recently observed increases in hypertension and diabetes prevalence are unlikely to be
8 attributable to improved data quality.
9

10
11
12
13
14
15
16
17
18 Our finding of the high validity of hypertension and diabetes in administrative data is
19 consistent with previous studies. Khokhar et al. reviewed validation studies of administrative
20 data for defining diabetes [19]. Of 18 studies reviewed, sensitivity ranged from 51.78% to 100%,
21 specificity ranged from 88% to 100%, PPV ranged from 21% to 99%, and NPV ranged from
22 60.32% to 99.63% [19]. Khokhar et al. reported that validity varied depending on study
23 population and administrative data sources. Our results were also consistent with previous
24 validation studies for hypertension [20-23]. Quan et al. reported that administrative data coding
25 for hypertension, based on a case definition of "2 physician claims within 2 years or 1
26 hospitalization" had the highest validity, with sensitivity 75%, specificity 94%, PPV 81%, and
27 NPV 92%. The high validity of coding for hypertension and diabetes may be related to a
28 minimum two year professional coder training program, central management of coding practice,
29 and resources allocation to record department, in Alberta [24,25].
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47 Our findings support the use of the DAD for surveillance and temporal trend analysis for
48 hypertension and diabetes. We found that data quality remained consistent regardless of patient
49 age, sex, or hospital location. In Canada, hypertension and diabetes are mostly managed in
50 outpatient clinics. Our validation study only contained data from hospitalizations. Therefore data
51 quality at outpatient sites over time was unknown. In Alberta, as is the case with most other
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Canadians provinces/territories, physicians submit claims with ICD diagnosis [26]. Cunningham et al. evaluated physician visit data quality (including inpatients and outpatient visits) in Alberta [27]. They concluded that physicians submitted a variety of ICD codes for claims and face validity of diagnosis coded in physician claims is substantially high [27]. Two Canadian studies (Quan et al. and Chen et al.) analyzed both inpatient and outpatient administrative data validity in defining hypertension and diabetes and did not find significant changes over years of 2001 and 2014 [6,12]. These two studies support our findings, although Januel et al reported that inpatient data validity improved after ICD-10 implementation in Switzerland [10].

Chronic disease surveillance is influenced by data quality. Because of imperfect data, accumulation of false positive and false negative cases over time using administrative data could result in biased estimation of hypertension and diabetes prevalence. Peng et al. evaluated these impacts on surveillance using sophisticated statistical methods and demonstrated that surveillance is less likely biased because false positive and negative cases are balanced out over time [28].

The major strength of this study is the scope. APPROACH is a prospective population based clinical registry with a very large number of observations over several years. This makes the assessment of time trends possible. However, our study is subject to limitations. First, our study assumes that the APPROACH registry is an accurate and suitable reference standard. Like many studies using clinical reference standards, our study does not confirm the reference standard accuracy. However, the use of trained clinicians for data entry, standardized definitions, and data quality and completeness check strategies within APPROACH support its use as a clinically accurate reference standard. The prospective data entry process within APPROACH also removes a major source of error that occurs as a result of time lag and

1
2
3 translation. Second, we did not validate outpatient data over time for defining hypertension and
4 diabetes. Third, we only validated data among patients who underwent coronary catheterization.
5
6 PPV and NPV are influenced by disease frequency, and the high prevalence of hypertension and
7 diabetes in patients with suspected coronary artery disease may produce higher estimates of PPV
8 and lower estimates of NPV than in general population. Finally, our analysis was limited to data
9 from Alberta. Data quality could vary by institutes and data collection management processes in
10 other settings [29]. Caution should be applied in generalizing our findings to other regions or
11 sites with less rigorous administrative data coding processes.
12
13
14
15
16
17
18
19
20
21

22
23 In conclusion, our study shows that DAD quality has remained consistent over 12 years
24 for both hypertension and diabetes, supporting the use of administrative data for surveillance of
25 these conditions. Further research on temporal trends in data quality of physician claims and
26 ambulatory care databases needs to be conducted to confirm the effect of data quality from these
27 sources on chronic disease prevalence trends.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. PHAC. Report from the Canadian Chronic Disease Surveillance System. [Online].; 2010 [cited 2015 April 27]. Available from: <http://www.phac-aspc.gc.ca/cd-mc/cvd-mcv/ccdss-snsmc-2010/2-1-eng.php>.
2. PHAC. Report from the Chronic Disease Surveillance System: Hypertension in Canada, 2010. Ottawa: Public Health Agency of Canada, Chronic Disease Surveillance Division; 2010.
3. PHAC. Diabetes in Canada: Facts and figures from a public health perspective. Ottawa: Public Health Agency of Canada, Chronic Disease Surveillance and Monitoring Division; 2011.
4. University of Manitoba. Population Health Research Data Repository: Administrative Health Databases. [Online].; 2011 [cited 2015 4 29]. Available from: http://umanitoba.ca/faculties/medicine/units/community_health_sciences/departmental_units/mchp/resource/repository/health_admin.html.
5. Allen V, Dodds L, Spencer A, Cummings E, MacDonald N, Kephart G. Application of a national administrative case definition of pre-existing diabetes mellitus in pregnancy. *Chronic Dis Inj Can*. 2012 June; 32(3): p. 113-20.
6. Chen G, Khan N, Walker R, Quan H. Validating ICD coding algorithms for diabetes mellitus from administrative data. *Diabetes Res Clin Pract*. 2010 August; 89(2): p. 189-95.
7. Daneshvar P, Forster A, Dervin G. Accuracy of administrative coding in identifying hip and knee primary replacements and revisions. *J Eval Clin Pract*. 2012 June; 18(3): p. 555-9.
8. De Coster C, Li B, Quan H. Comparison and validity of procedures coded with ICD-9-CM and ICD-10-CA/CCI. *Med Care*. 2008 June; 46(6): p. 627-34.
9. Hagen E, Rekand T, Gilhus N, Gronning M. Diagnostic coding accuracy for traumatic spinal cord injuries. *Spinal Cord*. 2009 May; 47(5): p. 367-71.
10. Januel J, Luthi J, Quan H, Borst F, Taffe P, Ghali W, et al. Improved accuracy of co-morbidity coding over time after the introduction of ICD-10 administrative data. *BMC Health Serv Res*. 2011 August; 18(11): p. 194.
11. Jette N, Reid A, Quan H, Hill M, Wiebe S. How accurate is ICD coding for epilepsy. *Epilepsia*. 2010 Jan; 51(1): p. 62-9.
12. Quan H, Khan N, Hemmelgarn BR, Tu K, Chen G, Campbell N, Hill MD, Ghali WA, McAlister FA; Hypertension Outcome and Surveillance Team of the Canadian Hypertension Education Programs. Validation of a case definition to define hypertension using administrative data. *Hypertension*. 2009 Dec; 54(6): p. 1423-8.
13. Quan H, Li B, Saunders LD, Parsons GA, Nilsson CI, Alibhai A, Ghali WA; IMECCHI Investigators. Assessing the validity of ICD-9-CM and ICD-10 administrative data in recording clinical conditions in a unique dually coded database. *Health Serv Res*. 2008 Aug; 43(4): p. 1424-41.
14. Reid A, St Germaine-Smith C, Liu M, Sadiq S, Quan H, Wiebe S, et al. Development and validation of a case definition for epilepsy for use with administrative health data. *Epilepsy Res*. 2012 Dec; 102(3): p. 173-9.
15. Schneeweiss S, Avorn J. A review of uses of health care utilization database for epidemiologic research on therapeutics. *Journal of Clinical Epidemiology*. 2005; 58: p. 323-337.

- 1 16. Canadian Institute for Health Information. Canadian Coding Standards for Version 2015 ICD-10-CA and CCI.
2 Ottawa, ON; CIHI; 2015.
- 3
- 4 17. Knudtson M, Ghali W. Overview of the Alberta Provincial Project for Outcome assessment in Coronary Heart
5 Disease. *Canadian Journal of Cardiology*. 2000; 16(10): p. 1225-30.
- 6
- 7 18. Southern D, Norris C, Quan H, Shrive FGP, Humphries K, Gao M, et al. An administrative data merging solution for
8 dealing with missing data in a clinical registry: adaptation from ICD-9 to ICD-10. *BMC Medical Research*
9 *Methodology*. 2008 Jan 23; 8(1).
- 10
- 11 19. Khokhar B, Jette N, Metcalfe A, Cunningham C, Quan H, Kaplan G, et al. Systematic Review of Validated Case
12 Definitions for Diabetes in ICD-9 and ICD-10 Coded data. Submitted - under review. 2015.
- 13
- 14 20. Muhajarine N, Mustard C, Roos L, Young T, Gelskey D. Comparison of survey and physician claims data for
15 detecting hypertension. *J Clin Epidemiology*. 1997 June; 50(6): p. 711-8.
- 16
- 17 21. Rector T, Wickstrom S, Shah M, Thomas Greenlee N, Rheault P, Rogowski J, et al. Specificity and sensitivity of
18 claims-based algorithms for identifying members of Medicare+Choice health plans that have chronic medical
19 conditions. *Health Serv Res*. 2003 Dec; 39(6): p. 1839-57.
- 20
- 21 22. Lix L, Yogendran M, Burchill C, Metge C, McKeen N, Moore D, et al. Defining and Validating Chronic Diseases: An
22 Administrative Data Approach. Winnipeg, Manitoba; Manitoba Centre for Health Policy; 2006.
- 23
- 24 23. Tu K, Campbell N, Chen X, Cauch-Dudek K, McAlister F. Accuracy of administrative databases in identifying
25 patients with hypertension. *Open Med*. 2007 Apr; 1(1): p. e18-e26.
- 26
- 27 24. Quan H, McAlister F, Khan N. The many faces of hypertension in Canada. *Curr Opin Cardiol*. 2014 July; 29(4): p.
28 354-9.
- 29
- 30 25. Hennessy D, Quan H, Faris P, Beck C. Do coder characteristics influence validity of ICD-10 hospital discharge
31 data? *BMC Health Serv Res*. 2010 Apr; 21(10): p. 99.
- 32
- 33 26. Lix LM, Walker R, Quan H, Nesdole R, Yang J, Chen G; CHEP-ORTF Hypertension Outcomes and Surveillance
34 Team. Features of physician services databases in Canada. *Chronic Dis Inj Can*. 2012 Sep; 32(4): p. 186-93.
- 35
- 36 27. Cunningham C, Cai P, Topps D, Svenson L, Jette N, Quan H. Mining rich health data from Canadian physician
37 claims: features and face validity. *BMC Res Notes*. 2014 Oct; 1(7): p. 682.
- 38
- 39 28. Peng M, Chen G, Lix LM, McAlister FA, Tu K, Campbell NR, Hemmelgarn BR, Svenson LW, Quan H; Hypertension
40 Outcomes Surveillance Team. Refining hypertension surveillance to account for potentially misclassified cases.
41 *PLOS One*. 2015 Mar; 10(3): p. e0119186.
- 42
- 43 29. Quan H, Smith M, Bartlett-Esquiland G, Johansen H, Tu K, Lix L; Hypertension Outcome and Surveillance Team.
44 Mining administrative health databases to advance medical science: geographical considerations and untapped
45 potential in Canada. *Can J Cardiol*. 2012 Mar-Apr; 28(2): p. 152-4.
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

* All Tables and Figures are also included in their Raw format in a separate Excel Spreadsheet

Table 1. Study population characteristics among patients underwent coronary artery cauterization in Alberta in 2002 and 2013

Patient Characteristics	Year 2002		Year 2013		Change between 2002 and 2013 (95% Confidence Interval)	
Age (Years)	63.8		62.6		-1.2 (-1.7, -0.6)	
Sex (Male)	69.9%		70.5%		0.7% (-1.2%, 2.5%)	
Location						
Calgary	48.1%		41.2%		-6.9% (-8.9%, -4.9%)	
Edmonton	42.6%		47.2%		4.6% (2.5%, 6.6%)	
Comorbidities (Prevalence)	APPROACH*	DAD*	APPROACH	DAD	APPROACH	DAD
Hyperlipidemia	69.5%	47.8%	60.8%	11.8%	-8.7% (-10.6%, -6.8%)	-36.0% (-37.7%, -34.2%)
Heart failure	11.4%	18.3%	8.1%	17.7%	-3.4% (-4.6%, -2.2%)	-0.6% (-2.2%, 1.0%)
Cerebrovascular disease	5.9%	3.8%	4.6%	1.8%	-1.3% (-2.2%, -0.4%)	-2.0% (-2.7%, -1.3%)
Peripheral vascular disease	7.3%	6.3%	2.9%	6.5%	-4.4% (-5.3%, -3.5%)	0.2% (-0.8%, 1.2%)
COPD	13.8%	10.9%	14.4%	9.2%	0.5% (-0.9%, 1.9%)	-1.7% (-2.9%, -0.4%)

*APPROACH: , the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) database



DAD: Canadian hospital discharge abstract administrative data

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Confidential

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1. Prevalence over time



*APPROACH: , the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) database

DAD: Canadian hospital discharge abstract administrative data

1
2
3
4 **Figure 2. Validity over time**
5
6





Table 2. Changes of prevalence of hypertension and diabetes between 2002 and 2013

	2002		2013		Change between 2002 and 2013 (95% CI)		
	APPROACH*	DAD*	APPROACH	DAD	APPROACH	DAD	
Hypertension	55.8%	54.9%	57.4%	57.8%	1.6% (-0.4%, 3.6%)	2.9% (0.9%, 4.9%)	
Age	18-64	48.5%	47.3%	49.1%	49.2%	0.6% (-2.2%, 3.4%)	1.9% (-0.9%, 4.7%)
	65+	63.5%	62.9%	67.7%	68.4%	4.2% (1.4%, 7.0%)	5.6% (2.8%, 8.4%)
Sex	Male	53.5%	53.2%	56.1%	56.7%	2.6% (0.2%, 5.0%)	3.5% (1.1%, 5.9%)
	Female	61.1%	58.9%	60.4%	60.4%	-0.7% (-4.3%, 2.9%)	1.5% (-2.2%, 5.2%)
City	Calgary	54.5%	55.6%	56.4%	56.1%	1.9% (-1.1%, 4.9%)	0.6% (-2.4%, 3.6%)
	Edmonton	56.9%	57.4%	55.4%	60.7%	-1.5% (-4.5%, 1.5%)	3.2% (0.2%, 6.2%)
Diabetes		23.5%	23.9%	23.6%	26.0%	0.1% (-1.6%, 1.8%)	2.1% (0.4%, 3.8%)
Age	18-64	19.5%	20.3%	19.6%	22.2%	0.0% (-2.2%, 2.3%)	1.9% (-0.4%, 4.2%)
	65+	27.6%	27.7%	28.6%	30.7%	1.0% (-1.7%, 3.6%)	3.1% (0.4%, 5.8%)
Sex	Male	22.6%	23.0%	22.8%	25.7%	0.2% (-1.8%, 2.2%)	2.7% (0.6%, 4.8%)
	Female	25.4%	26.0%	25.3%	26.8%	0.0% (-3.3%, 3.2%)	0.9% (-2.4%, 4.2%)
City	Calgary	24.0%	24.4%	22.8%	26.4%	-1.2% (-3.8%, 1.4%)	2.0% (-0.6%, 4.6%)
	Edmonton	22.8%	24.0%	23.0%	25.3%	0.2% (-2.4%, 2.7%)	1.3% (-1.4%, 3.9%)

*APPROACH: the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease

(APPROACH) database

DAD: Canadian hospital discharge abstract administrative data

Table 3. Validity of hypertension and diabetes in hospital discharge abstract administrative data

Year	Hypertension					Diabetes				
	Sn. (%), (95%CI)	Sp. (%), (95% CI)	PPV (%), (95% CI)	NPV (%), (95% CI)		Sn. (%), (95%CI)	Sp. (%), (95% CI)	PPV (%), (95% CI)	NPV (%), (95% CI)	
2002	82.2, (79.9-84.5)	79.6, (76.9-82.3)	83.6, (81.3-85.8)	78.0, (75.3-80.7)		92.1, (89.7-94.6)	97.0, (96.2-97.9)	90.5, (87.8-93.1)	97.6, (96.8-98.4)	
2003	74.6, (72.5-76.7)	79.8, (77.3-82.3)	85.9, (84.1-87.7)	65.5, (62.9-68.2)		89.6, (87.2-92.0)	96.3, (95.5-97.2)	88.2, (85.6-90.7)	96.8, (96.0-97.6)	
2004	77.1, (75.1-79.1)	78.1, (75.6-80.6)	84.4, (82.6-86.3)	68.9, (66.3-71.5)		83.8, (80.8-86.7)	96.7, (95.9-97.4)	87.5, (84.7-90.2)	95.5, (94.7-96.4)	
2005	75.5, (73.5-77.6)	80.9, (78.4-83.3)	87.0, (85.3-88.7)	66.1, (63.4-68.7)		81.5, (78.5-84.5)	96.6, (95.8-97.4)	87.9, (85.3-90.6)	94.5, (93.5-95.4)	
2006	79.5, (77.5-81.5)	78.8, (76.3-81.3)	85.0, (83.2-86.9)	71.7, (69.1-74.4)		88.9, (86.4-91.5)	96.6, (95.8-97.4)	88.1, (85.5-90.7)	96.8, (96.1-97.6)	
2007	78.5, (76.4-80.6)	71.9, (69.1-74.6)	80.5, (78.4-82.5)	69.3, (66.5-72.1)		91.1, (88.8-93.5)	95.4, (94.4-96.3)	85.6, (82.9-88.4)	97.3, (96.5-98.0)	
2008	80.0, (77.9-82.0)	74.0, (71.3-76.7)	81.9, (79.9-83.9)	71.5, (68.7-74.3)		90.8, (88.4-93.3)	95.5, (94.6-96.5)	85.2, (82.3-88.1)	97.4, (96.6-98.1)	
2009	79.3, (77.2-81.4)	74.5, (71.7-77.2)	81.9, (79.9-84.0)	71.1, (68.3-73.8)		90.7, (88.3-93.1)	95.0, (94.0-96.0)	84.6, (81.8-87.5)	97.1, (96.3-97.9)	
2010	81.8, (79.8-83.7)	72.1, (69.3-74.8)	81.2, (79.2-83.1)	72.9, (70.1-75.6)		91.8, (89.5-94.0)	95.4, (94.5-96.4)	85.3, (82.5-88.1)	97.6, (96.9-98.3)	
2011	80.8, (78.8-82.9)	71.2, (68.4-73.9)	79.4, (77.3-81.4)	73.0, (70.3-75.7)		91.4, (89.1-93.7)	93.9, (92.9-95.0)	81.5, (78.5-84.5)	97.4, (96.7-98.1)	
2012	82.5, (80.6-84.4)	71.0, (68.3-73.7)	79.8, (77.8-81.7)	74.5, (71.9-77.1)		91.6, (89.4-93.8)	93.9, (92.9-95.0)	81.4, (78.5-84.3)	97.5, (96.8-98.2)	
2013	79.8, (77.8-81.8)	71.9, (69.3-74.5)	79.3, (77.3-81.3)	72.5, (70.0-75.1)		90.7, (88.5-93.0)	94.0, (93.0-95.0)	82.3, (79.5-85.1)	97.0, (96.3-97.8)	
Age	76.9, (73.9-79.9)	77.6, (74.6-80.5)	76.8, (73.8-79.8)	77.7, (74.7-80.6)		89.4, (85.9-92.9)	94.2, (92.9-95.5)	78.9, (74.5-83.3)	97.3, (96.4-98.3)	
65+	82.4, (79.8-85.0)	60.8, (56.0-65.7)	81.5, (78.8-84.1)	62.3, (57.4-67.1)		91.8, (88.9-94.7)	93.7, (92.1-95.3)	85.3, (81.8-88.9)	96.6, (95.4-97.8)	
Sex	79.2, (76.8-81.6)	72.1, (69.1-75.2)	78.4, (76.0-80.9)	73.1, (70.1-76.1)		91.8, (89.2-94.3)	93.9, (92.7-95.1)	81.7, (78.3-85.1)	97.5, (96.7-98.3)	
Male	81.1, (77.6-84.6)	71.3, (66.3-76.3)	81.2, (77.7-84.6)	71.2, (66.2-76.1)		88.5, (84.1-92.9)	94.1, (92.3-96.0)	83.7, (78.7-88.6)	96.0, (94.4-97.6)	
Female	76.3, (73.0-79.7)	70.1, (66.0-74.1)	76.8, (73.5-80.1)	69.6, (65.5-73.6)		91.6, (88.2-95.0)	92.8, (91.1-94.6)	79.1, (74.5-83.7)	97.4, (96.3-98.5)	
City	86.5, (84.0-89.0)	71.5, (67.8-75.2)	79.0, (76.2-81.9)	81.0, (77.6-84.4)		91.7, (88.6-94.9)	94.5, (93.1-95.9)	83.3, (79.3-87.4)	97.5, (96.5-98.5)	
Edmonton										

Table 1. Study population characteristics among patients who underwent coronary artery catheterization i

Patient Characteristics	2002		2013		Change
Age	63.8		62.6		-1.2 (-
Sex (Male)	69.9%		70.5%		0.7% (-1
Location					
Calgary	48.1%		41.2%		-6.9% (-8
Edmonton	42.6%		47.2%		4.6% (2
Common Comorbidities (Prevalence)					
	APPROACH*	DAD*	APPROACH	DAD	APPROACH
Hyperlipidemia	69.5%	47.8%	60.8%	11.8%	-8.7% (-10.6%, -6.8%)
Heart Failure	11.4%	18.3%	8.1%	17.7%	-3.4% (-4.6%, -2.2%)
CEVD	5.9%	3.8%	4.6%	1.8%	-1.3% (-2.2%, -0.4%)
PVD	7.3%	6.3%	2.9%	6.5%	-4.4% (-5.3%, -3.5%)
COPD	13.8%	10.9%	14.4%	9.2%	0.5% (-0.9%, 1.9%)

* APPROACH; Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease

* DAD; Hospital Discharge Abstract Database

1
2 **n Alberta in 2002 and 2013**
3

4	e (95% CI)
5	1.7, -0.6)
6	..2%, 2.5%)
7	
8	
9	3.9%, -4.9%)
10	.5%, 6.6%)
11	
12	
13	
14	DAD
15	
16	-36.0% (-37.7%, -34.2%)
17	-0.6% (-2.2%, 1.0%)
18	-2.0% (-2.7%, -1.3%)
19	0.2% (-0.8%, 1.2%)
20	
21	-1.7% (-2.9%, -0.4%)
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

Confidential

Table 2. Changes of prevalence of hypertension and diabetes between 2002 and 2013

	2002		2013		Change between 20	
	APPROACH*	DAD*	APPROACH	DAD	APPROACH	
Hypertension	55.8%	54.9%	57.4%	57.8%	1.6% (-0.4%, 3.6%)	
Age	18-64	48.5%	47.3%	49.1%	49.2%	0.6% (-2.2%, 3.4%)
	65+	63.5%	62.9%	67.7%	68.4%	4.2% (1.4%, 7.0%)
Sex	Male	53.5%	53.2%	56.1%	56.7%	2.6% (0.2%, 5.0%)
	Female	61.1%	58.9%	60.4%	60.4%	-0.7% (-4.3%, 2.9%)
City	Calgary	54.5%	55.6%	56.4%	56.1%	1.9% (-1.1%, 4.9%)
	Edmonton	56.9%	57.4%	55.4%	60.7%	-1.5% (-4.5%, 1.5%)
Diabetes	23.5%	23.9%	23.6%	26.0%	0.1% (-1.6%, 1.8%)	
Age	18-64	19.5%	20.3%	19.6%	22.2%	0.0% (-2.2%, 2.3%)
	65+	27.6%	27.7%	28.6%	30.7%	1.0% (-1.7%, 3.6%)
Sex	Male	22.6%	23.0%	22.8%	25.7%	0.2% (-1.8%, 2.2%)
	Female	25.4%	26.0%	25.3%	26.8%	0.0% (-3.3%, 3.2%)
City	Calgary	24.0%	24.4%	22.8%	26.4%	-1.2% (-3.8%, 1.4%)
	Edmonton	22.8%	24.0%	23.0%	25.3%	0.2% (-2.4%, 2.7%)

* APPROACH; Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease

* DAD; Hospital Discharge Abstract Data

02 and 2013 (95% CI)	
DAD	
	2.9% (0.9%, 4.9%)
	1.9% (-0.9%, 4.7%)
	5.6% (2.8%, 8.4%)
	3.5% (1.1%, 5.9%)
	1.5% (-2.2%, 5.1%)
	0.6% (-2.4%, 3.6%)
	3.2% (0.2%, 6.2%)
	2.1% (0.4%, 3.9%)
	1.9% (-0.4%, 4.2%)
	3.1% (0.4%, 5.8%)
	2.7% (0.6%, 4.7%)
	0.9% (-2.4%, 4.1%)
	2.0% (-0.6%, 4.6%)
	1.3% (-1.4%, 3.9%)

Confidential

Table 3. Validity of hypertension and diabetes in hospital discharge abstract data

Year		Hypertension			
		Sn. (%), (95%CI)	Sp. (%), (95% CI)	PPV (%), (95% CI)	NPV (%), (95% CI)
	2002	82.2, (79.9-84.5)	79.6, (76.9-82.3)	83.6, (81.3-85.8)	78.0, (75.3-80.7)
	2003	74.6, (72.5-76.7)	79.8, (77.3-82.3)	85.9, (84.1-87.7)	65.5, (62.9-68.2)
	2004	77.1, (75.1-79.1)	78.1, (75.6-80.6)	84.4, (82.6-86.3)	68.9, (66.3-71.5)
	2005	75.5, (73.5-77.6)	80.9, (78.4-83.3)	87.0, (85.3-88.7)	66.1, (63.4-68.7)
	2006	79.5, (77.5-81.5)	78.8, (76.3-81.3)	85.0, (83.2-86.9)	71.7, (69.1-74.4)
	2007	78.5, (76.4-80.6)	71.9, (69.1-74.6)	80.5, (78.4-82.5)	69.3, (66.5-72.1)
	2008	80.0, (77.9-82.0)	74.0, (71.3-76.7)	81.9, (79.9-83.9)	71.5, (68.7-74.3)
	2009	79.3, (77.2-81.4)	74.5, (71.7-77.2)	81.9, (79.9-84.0)	71.1, (68.3-73.8)
	2010	81.8, (79.8-83.7)	72.1, (69.3-74.8)	81.2, (79.2-83.1)	72.9, (70.1-75.6)
	2011	80.8, (78.8-82.9)	71.2, (68.4-73.9)	79.4, (77.3-81.4)	73.0, (70.3-75.7)
	2012	82.5, (80.6-84.4)	71.0, (68.3-73.7)	79.8, (77.8-81.7)	74.5, (71.9-77.1)
	2013	79.8, (77.8-81.8)	71.9, (69.3-74.5)	79.3, (77.3-81.3)	72.5, (70.0-75.1)
Age	<65	76.9, (73.9-79.9)	77.6, (74.6-80.5)	76.8, (73.8-79.8)	77.7, (74.7-80.6)
	65+	82.4, (79.8-85.0)	60.8, (56.0-65.7)	81.5, (78.8-84.1)	62.3, (57.4-67.1)
Sex	Male	79.2, (76.8-81.6)	72.1, (69.1-75.2)	78.4, (76.0-80.9)	73.1, (70.1-76.1)
	Female	81.1, (77.6-84.6)	71.3, (66.3-76.3)	81.2, (77.7-84.6)	71.2, (66.2-76.1)
City	Calgary	76.3, (73.0-79.7)	70.1, (66.0-74.1)	76.8, (73.5-80.1)	69.6, (65.5-73.6)
	Edmonton	86.5, (84.0-89.0)	71.5, (67.8-75.2)	79.0, (76.2-81.9)	81.0, (77.6-84.4)

Diabetes			
Sn. (%), (95%CI)	Sp. (%), (95% CI)	PPV (%), (95% CI)	NPV (%), (95% CI)
92.1, (89.7-94.6)	97.0, (96.2-97.9)	90.5, (87.8-93.1)	97.6, (96.8-98.4)
89.6, (87.2-92.0)	96.3, (95.5-97.2)	88.2, (85.6-90.7)	96.8, (96.0-97.6)
83.8, (80.8-86.7)	96.7, (95.9-97.4)	87.5, (84.7-90.2)	95.5, (94.7-96.4)
81.5, (78.5-84.5)	96.6, (95.8-97.4)	87.9, (85.3-90.6)	94.5, (93.5-95.4)
88.9, (86.4-91.5)	96.6, (95.8-97.4)	88.1, (85.5-90.7)	96.8, (96.1-97.6)
91.1, (88.8-93.5)	95.4, (94.4-96.3)	85.6, (82.9-88.4)	97.3, (96.5-98.0)
90.8, (88.4-93.3)	95.5, (94.6-96.5)	85.2, (82.3-88.1)	97.4, (96.6-98.1)
90.7, (88.3-93.1)	95.0, (94.0-96.0)	84.6, (81.8-87.5)	97.1, (96.3-97.9)
91.8, (89.5-94.0)	95.4, (94.5-96.4)	85.3, (82.5-88.1)	97.6, (96.9-98.3)
91.4, (89.1-93.7)	93.9, (92.9-95.0)	81.5, (78.5-84.5)	97.4, (96.7-98.1)
91.6, (89.4-93.8)	93.9, (92.9-95.0)	81.4, (78.5-84.3)	97.5, (96.8-98.2)
90.7, (88.5-93.0)	94.0, (93.0-95.0)	82.3, (79.5-85.1)	97.0, (96.3-97.8)
89.4, (85.9-92.9)	94.2, (92.9-95.5)	78.9, (74.5-83.3)	97.3, (96.4-98.3)
91.8, (88.9-94.7)	93.7, (92.1-95.3)	85.3, (81.8-88.9)	96.6, (95.4-97.8)
91.8, (89.2-94.3)	93.9, (92.7-95.1)	81.7, (78.3-85.1)	97.5, (96.7-98.3)
88.5, (84.1-92.9)	94.1, (92.3-96.0)	83.7, (78.7-88.6)	96.0, (94.4-97.6)
91.6, (88.2-95.0)	92.8, (91.1-94.6)	79.1, (74.5-83.7)	97.4, (96.3-98.5)
91.7, (88.6-94.9)	94.5, (93.1-95.9)	83.3, (79.3-87.4)	97.5, (96.5-98.5)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1. Prevalence over time




Figure 2. Validity over time

